Saturday, 31 October 2026European Markets

NORWEGIAN AIR SHUT Stock Is 28% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORWEGIAN AIR SHUT (Oslo Børs Benchmark Index_GI: NAS.OL) jumped by a staggering 28.1% in 21 sessions from kr10.07 to kr12.90 at 14:45 EST on Monday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 0.29% to kr1,215.57, after three consecutive sessions in a row of losses.

NORWEGIAN AIR SHUT's last close was kr12.90, 1.3% under its 52-week high of kr13.07.

About NORWEGIAN AIR SHUT

Norwegian Air Shuttle ASA, together with its subsidiaries, provides air travel services in Norway and internationally. It operates short haul point to point domestic and cross border flights services. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. It operates a fleet of 70 aircrafts. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.

Earnings Per Share

As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of kr0.97.

PE Ratio

NORWEGIAN AIR SHUT has a trailing twelve months price to earnings ratio of 13.3. Meaning, the purchaser of the share is investing kr13.3 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.91%.

Moving Average

NORWEGIAN AIR SHUT's worth is way above its 50-day moving average of kr10.79 and way above its 200-day moving average of kr9.19.

More news about NORWEGIAN AIR SHUT (NAS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com